- Home
- ST vs PRAX Comparison
ST vs PRAX Comparison
Compare ST & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ST
- PRAX
- Stock Information
- Founded
- ST 1916
- PRAX 2015
- Country
- ST United States
- PRAX United States
- Employees
- ST N/A
- PRAX N/A
- Industry
- ST Industrial Machinery/Components
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- ST Industrials
- PRAX Health Care
- Exchange
- ST Nasdaq
- PRAX Nasdaq
- Market Cap
- ST 4.6B
- PRAX 4.0B
- IPO Year
- ST 2010
- PRAX 2020
- Fundamental
- Price
- ST $30.69
- PRAX $167.82
- Analyst Decision
- ST Buy
- PRAX Strong Buy
- Analyst Count
- ST 14
- PRAX 12
- Target Price
- ST $35.14
- PRAX $210.25
- AVG Volume (30 Days)
- ST 1.3M
- PRAX 1.6M
- Earning Date
- ST 10-28-2025
- PRAX 11-05-2025
- Dividend Yield
- ST 1.55%
- PRAX N/A
- EPS Growth
- ST N/A
- PRAX N/A
- EPS
- ST N/A
- PRAX N/A
- Revenue
- ST $3,694,307,000.00
- PRAX $7,463,000.00
- Revenue This Year
- ST N/A
- PRAX N/A
- Revenue Next Year
- ST $3.36
- PRAX $44.43
- P/E Ratio
- ST N/A
- PRAX N/A
- Revenue Growth
- ST N/A
- PRAX 364.98
- 52 Week Low
- ST $17.32
- PRAX $26.70
- 52 Week High
- ST $34.31
- PRAX $206.71
- Technical
- Relative Strength Index (RSI)
- ST 45.24
- PRAX 59.66
- Support Level
- ST $30.75
- PRAX $154.46
- Resistance Level
- ST $32.30
- PRAX $175.96
- Average True Range (ATR)
- ST 1.14
- PRAX 13.55
- MACD
- ST -0.13
- PRAX -5.17
- Stochastic Oscillator
- ST 20.22
- PRAX 25.73
About ST Sensata Technologies Holding plc
Sensata Technologies is a global supplier of sensors for transportation and industrial applications. Sensata sells a bevy of pressure, temperature, force, and position sensors into the automotive, heavy vehicle, industrial, heating, ventilation, and cooling, and aerospace markets. The majority of the firm's revenue comes from the automotive market, where it focuses on bumper-in applications.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.